Extended Anticoagulant Treatment with Full-or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study
ContributorsMahé, Isabelle ; Agnelli, Giancarlo; Ay, Cihan; Bamias, Aristotelis ; Becattini, Cecilia; Carrier, Marc; Chapelle, Céline; Cohen, Alexander T; Girard, Philippe; Huisman, Menno V; Klok, Frederikus A ; López-Núñez, Juan J; Maraveyas, Anthony; Mayeur, Didier; Mir, Olivier; Monreal, Manuel; Righini, Marc Philip; Samama, Charles M; Syrigos, Kostas; Szmit, Sebastian; Torbicki, Adam; Verhamme, Peter ; Vicaut, Eric; Wang, Tzu-Fei; Meyer, Guy; Laporte, Silvy
Published inThrombosis and haemostasis, vol. 122, no. 4, p. 646-656
Publication date2022-04
First online date2021-09-17
Abstract
Keywords
- Anticoagulants / adverse effects
- Hemorrhage / epidemiology
- Humans
- Neoplasms / drug therapy
- Pyrazoles
- Pyridones / adverse effects
- Venous Thromboembolism / diagnosis
- Venous Thromboembolism / drug therapy
- Venous Thromboembolism / prevention & control
- Anticoagulants
- Pyridones
- Apixaban
Affiliation
Research group
Citation (ISO format)
MAHÉ, Isabelle et al. Extended Anticoagulant Treatment with Full-or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. In: Thrombosis and haemostasis, 2022, vol. 122, n° 4, p. 646–656. doi: 10.1055/a-1647-9896
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:161636
- DOI : 10.1055/a-1647-9896
- PMID : 34535037
- PMCID : PMC9113855
ISSN of the journal0340-6245